0000899243-23-014886.txt : 20230608 0000899243-23-014886.hdr.sgml : 20230608 20230608163835 ACCESSION NUMBER: 0000899243-23-014886 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230608 FILED AS OF DATE: 20230608 DATE AS OF CHANGE: 20230608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sandoval Elisabeth CENTRAL INDEX KEY: 0001632295 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39041 FILM NUMBER: 231002490 MAIL ADDRESS: STREET 1: C/O KYTHERA BIOPHARMACEUTICALS, INC. STREET 2: 30930 RUSSELL RANCH ROAD, 3RD FLOOR CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Satsuma Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001692830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813039831 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4819 EMPEROR BOULEVARD STREET 2: SUITE 340 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 415-505-0809 MAIL ADDRESS: STREET 1: 4819 EMPEROR BOULEVARD STREET 2: SUITE 340 CITY: DURHAM STATE: NC ZIP: 27703 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-08 1 0001692830 Satsuma Pharmaceuticals, Inc. STSA 0001632295 Sandoval Elisabeth C/O SATSUMA PHARMACEUTICALS, INC. 400 OYSTER POINT BOULEVARD, SUITE 221 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 0 Stock Option (right to buy) 26.99 2023-06-08 4 D 0 10000 0.00 D Common Stock 10000 0 D Stock Option (right to buy) 4.60 2023-06-08 4 D 0 20000 0.00 D Common Stock 20000 0 D Stock Option (right to buy) 3.46 2023-06-08 4 D 0 30000 0.00 D Common Stock 30000 0 D Stock Option (right to buy) 4.56 2023-06-08 4 D 0 14893 0.00 D Common Stock 14893 0 D Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. /s/ Thomas P. O'Neil as Attorney in Fact for Elisabeth Sandoval 2023-06-08